Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.
Latest from Joseph Haas
The bigger biopharma M&A deals seen particularly during the second half of 2025 should continue into 2026, PwC said, driven by LOEs and a more precision-driven process.
With registrational Phase II data in Stiff Person Syndrome, Kyverna intends to file a BLA for mivocabtagene autoleucel in 2026. Longer term, it hopes to get the CAR-T approved for myasthenia gravis.
Arcus is ending development of its TIGIT-targeted antibody domvanalimab after it was determined a Phase III study would not show a survival benefit in gastrointestinal cancers.
Triple agonist retatrutide yielded 28.7% weight loss at 68 weeks, besting Zepbound’s Phase III data, while also showing benefit in knee osteoarthritis pain.
Pfizer’s Phase III data show an 8.6-month increase in progression-free survival for Tukysa as first-line maintenance treatment of HER2+ breast cancer, a setting where the standard of care hasn’t changed since 2012.
With its M&A war chest diminished and still seeking to add to its weight-management pipeline, Pfizer obtains an oral GLP-1 analog from Fosun subsidiary YaoPharma.